(Alliance News) - Clinigen Group PLC reiterated its annual earnings forecast on Wednesday after a "solid performance" in its first half but warned of the continued risks presented by the Covid-19 Omicron variant.
"During the first half of the year we have seen a solid performance across both the Services and Products divisions," commented Chief Executive Shaun Chilton.
The Staffordshire-based pharmaceuticals and services provider expects financial year 2022 earnings before interest, tax, depreciation and amortisation growth of between 5% and 10%.
"We remain mindful of the continued prevalence of the Covid-19 Omicron variant, which has the potential to impact our principal markets. However, we continue to perform well on those elements within our control and remain focused on building the lifecycle platform to service the needs of pharma companies and healthcare professionals around the globe," added Chilton.
Shares were 0.4% lower at 918.61 pence on Wednesday morning in London.
By Will Paige; willpaige@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
